GAITHERSBURG, Md., July 23, 2015 (GLOBE NEWSWIRE) -- The American Academy of Professional Coders (AAPC) and Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced a multi-year partnership that will elevate the business of healthcare through the creation of educational materials to promote best practices in wound care treatment and business.
Through this novel partnership, AAPC and Nuo Therapeutics will develop written and online materials to educate professional medical office staff in the specialty area of wound care.
"This is the first partnership of its kind focused on educating medical billers and coders on best practices in the specialty area of wound care," said Jeremy Schow, Vice President of Enterprise Solutions for AAPC. "We are excited to be working with Nuo Therapeutics to bring these much needed educational materials to our members."
The first program to launch under this new initiative will be the Wound Care Learning Path, which is a series of interactive modules focusing on key topics in wound care and the coding and billing of treatments in this specialty area. The first module, Wound Care 101, will focus on providing billers and coders a foundational knowledge of wound care, and is expected to launch this summer. Once available, the program will also provide participants with credits related to the ongoing educational requirements of their AAPC certification.
"With the healthcare landscape constantly changing, and the ICD-10 implementation on the horizon, we understand the importance of proper coding to the success of our customers' businesses and in turn, their ability to provide optimal care for their patients," said Dean Tozer, Chief Commercial Officer of Nuo Therapeutics. "We are pleased to be partnering with AAPC to make this program available to billers and coders across the country, as we believe it will further the business of healthcare generally, and wound care specifically."
AAPC brings an expertise in medical billing and coding, as well as a deep experience in development of written and online instructional materials designed specifically for Billers and Coders. Nuo Therapeutics has in-depth content knowledge and industry leadership in the area of wound care.
Founded in 1988, AAPC provides education and professional certification to physician-based medical coders. AAPC is the nation's largest training and credentialing organization for the business side of healthcare. AAPC has more than 141,000 certified members in medical coding, medical billing, medical auditing, compliance, and practice management, who represent the highest level of expertise in the industry.
About Nuo Therapeutics
Nuo Therapeutics, Inc. (the "Company") is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix, is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information please visit www.nuot.com.
Aurix is the first platelet and plasma therapy system to be cleared by FDA for the management of a broad range of ulcers and exuding wounds, including:
- All types (diabetic foot ulcer, venous leg ulcer, pressure ulcer, etc.),
- All morphologies (partial thickness, full thickness and complex wounds),
- All severities (tunneling, sinus tract, bone, tendon and hardware exposure).
Unlike other cellular-based treatment options, Aurix is an autologous biodynamic hematogel that is derived from a patient's own platelets and plasma. The product is used at the point-of-care to stimulate the natural wound healing process from deep within the wound bed. For additional information, please visit www.AurixSystem.com.
Safe Harbor Statement
This press release contains "forward-looking statements" pursuant to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "believes", "forecasted," "projects," "is expected," "remain confident," "will", "estimate," "target," "plan," "should", "would," "is likely," "may," and/or similar expressions. The information contained in the forward-looking statements, including without limitation those about the Company's estimated revenue, product sales, product placements, gross margin, operating expenses and other income or expenses, is inherently uncertain, and the Company's actual results may differ materially from these forward-looking statements. These forward-looking statements include, without limitation, statements concerning the Company's ability to successfully launch and rebrand its wound care system in the timeframe and to the extent anticipated, product placement with the VA System, enlistment of wound care centers, the Company's ability to estimate the potential of the wound care market and to commercialize any of its rebranded products / therapies, successfully execute its Aurix sales and commercialization strategies, the Company's ability to commercialize Aurix as expected and derive financial and commercial benefits of such launch, to achieve Aurix expected reimbursement rates beyond 2015, the Company's ability to comply with the debt covenants and restrictions under its existing loan facilities including from Deerfield Management Company, L.P., the Company's ability to realize expected benefits from the Arthrex licensing arrangement, the Company's ability to collect the data necessary for the grant of the unconditional coverage, the Company's ability to continue in its efforts to expand in the wound care market, and its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatment. Forward-looking statements are also subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks as to whether the Company may achieve future favorable CMS determinations relating to the reimbursement rates for Aurix, the Company's ability to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's ability to realize its expectations of favorable future dialogue with potential strategic partners, its ability to identify, proceed with and consummate strategic initiatives , its ability to successfully manage contemplated clinical trials, its ability to manage and address the capital needs, human resources, management, compliance and other challenges of a larger, more complex and integrated business enterprise, the viability and effectiveness of the Company's sales approach and overall marketing strategies, its ability to secure Medicare reimbursements at adequate levels; its ability to realize commercial success or acceptance by the medical community, the Company's ability to raise additional capital or issue additional securities and to continue as a going concern, and the Company's ability to execute on its strategy to market the Aurix System as contemplated, and other risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Undue reliance should not be placed on forward-looking information. Nuo Therapeutics operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Except as is expressly required by the federal securities laws, Nuo Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Nuo Therapeutics, Inc. Martin Rosendale, CEO 240-499-2680 Investors: Lee Roth, The Ruth Group 646-536-7012 email@example.com
Source:Nuo Therapeutics, Inc.